Laura Evangelista, Lorenzo Muraglia, Priscilla Guglielmo, Roberta Zanca, Carlo Vallone, Jelena Jandric, Demetrio Aricò, Nicolò Buffi, Giovanni Lughezzani
{"title":"初级评分作为中危前列腺癌的预测指标：来自PSMA PET/CT成像的见解","authors":"Laura Evangelista, Lorenzo Muraglia, Priscilla Guglielmo, Roberta Zanca, Carlo Vallone, Jelena Jandric, Demetrio Aricò, Nicolò Buffi, Giovanni Lughezzani","doi":"10.1007/s13139-025-00920-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to determine whether the PRIMARY Score on prostate specific membrane antigen (PSMA) positron emission tomography/compute tomography (PET/CT) can predict adverse pathology and prognosis in patients with intermediate-risk prostate cancer (PCa).</p><p><strong>Materials and methods: </strong>This is a retrospective, multicenter analysis of patients diagnosed with intermediate risk PCa. Patients were staged using pelvic multiparametric magnetic resonance imaging (mpMRI) and radiolabeled PSMA PET/CT, either [68 Ga]Ga-PSMA-11 or [18F]F-PSMA1007, to evaluate the extent of disease before initiating appropriate treatment. PI-RADS Version 2.1 and PRIMARY score were used for a quantitative analysis, respectively for mpMRI and PSMA PET/CT. Biochemical recurrence of disease was defined as a post-operative serum PSA > 0.2 ng/ml on two separate occasions at minimum 2-week intervals.</p><p><strong>Results: </strong>Seventy-eight intermediate-risk PCa patients were enrolled. PRIMARY scores > 3 was found in 62% of favorable (n = 50) and 71% of unfavorable cases (n = 28). Gleason score changes occurred in 20% of favorable-risk patients, with 90% having a PRIMARY score > 3. Biochemical recurrence was observed in 17% of patients during follow-up, predominantly among favorable-risk cases (13%), where most had Gleason score changes and a PRIMARY score > 3.</p><p><strong>Conclusions: </strong>These results highlight the predictive value of the PRIMARY score for Gleason score changes.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13139-025-00920-6.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"59 4","pages":"255-260"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267801/pdf/","citationCount":"0","resultStr":"{\"title\":\"Primary Score as a Predictive Marker in Intermediate-Risk Prostate Cancer: Insights from PSMA PET/CT Imaging.\",\"authors\":\"Laura Evangelista, Lorenzo Muraglia, Priscilla Guglielmo, Roberta Zanca, Carlo Vallone, Jelena Jandric, Demetrio Aricò, Nicolò Buffi, Giovanni Lughezzani\",\"doi\":\"10.1007/s13139-025-00920-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to determine whether the PRIMARY Score on prostate specific membrane antigen (PSMA) positron emission tomography/compute tomography (PET/CT) can predict adverse pathology and prognosis in patients with intermediate-risk prostate cancer (PCa).</p><p><strong>Materials and methods: </strong>This is a retrospective, multicenter analysis of patients diagnosed with intermediate risk PCa. Patients were staged using pelvic multiparametric magnetic resonance imaging (mpMRI) and radiolabeled PSMA PET/CT, either [68 Ga]Ga-PSMA-11 or [18F]F-PSMA1007, to evaluate the extent of disease before initiating appropriate treatment. PI-RADS Version 2.1 and PRIMARY score were used for a quantitative analysis, respectively for mpMRI and PSMA PET/CT. Biochemical recurrence of disease was defined as a post-operative serum PSA > 0.2 ng/ml on two separate occasions at minimum 2-week intervals.</p><p><strong>Results: </strong>Seventy-eight intermediate-risk PCa patients were enrolled. PRIMARY scores > 3 was found in 62% of favorable (n = 50) and 71% of unfavorable cases (n = 28). Gleason score changes occurred in 20% of favorable-risk patients, with 90% having a PRIMARY score > 3. Biochemical recurrence was observed in 17% of patients during follow-up, predominantly among favorable-risk cases (13%), where most had Gleason score changes and a PRIMARY score > 3.</p><p><strong>Conclusions: </strong>These results highlight the predictive value of the PRIMARY score for Gleason score changes.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13139-025-00920-6.</p>\",\"PeriodicalId\":19384,\"journal\":{\"name\":\"Nuclear Medicine and Molecular Imaging\",\"volume\":\"59 4\",\"pages\":\"255-260\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267801/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13139-025-00920-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine and Molecular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13139-025-00920-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Primary Score as a Predictive Marker in Intermediate-Risk Prostate Cancer: Insights from PSMA PET/CT Imaging.
Purpose: This study aimed to determine whether the PRIMARY Score on prostate specific membrane antigen (PSMA) positron emission tomography/compute tomography (PET/CT) can predict adverse pathology and prognosis in patients with intermediate-risk prostate cancer (PCa).
Materials and methods: This is a retrospective, multicenter analysis of patients diagnosed with intermediate risk PCa. Patients were staged using pelvic multiparametric magnetic resonance imaging (mpMRI) and radiolabeled PSMA PET/CT, either [68 Ga]Ga-PSMA-11 or [18F]F-PSMA1007, to evaluate the extent of disease before initiating appropriate treatment. PI-RADS Version 2.1 and PRIMARY score were used for a quantitative analysis, respectively for mpMRI and PSMA PET/CT. Biochemical recurrence of disease was defined as a post-operative serum PSA > 0.2 ng/ml on two separate occasions at minimum 2-week intervals.
Results: Seventy-eight intermediate-risk PCa patients were enrolled. PRIMARY scores > 3 was found in 62% of favorable (n = 50) and 71% of unfavorable cases (n = 28). Gleason score changes occurred in 20% of favorable-risk patients, with 90% having a PRIMARY score > 3. Biochemical recurrence was observed in 17% of patients during follow-up, predominantly among favorable-risk cases (13%), where most had Gleason score changes and a PRIMARY score > 3.
Conclusions: These results highlight the predictive value of the PRIMARY score for Gleason score changes.
Supplementary information: The online version contains supplementary material available at 10.1007/s13139-025-00920-6.
期刊介绍：
Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, case reports, editorials, interesting images, and letters to the editor.
The Korean Society of Nuclear Medicine (KSNM)
KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
